Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status
Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s ...
Zacks Investment Research on MSN13h
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago. These figures are adjusted ...
Tracking Baker Brothers Portfolio - Q4 2024 Update
Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Zacks Investment Research on MSN2d
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago. These ...